Skip to content

Research at St Andrews

Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label phase II clinical trial (SAEFRIF)

Research output: Contribution to journalArticle

Author(s)

Ruth Nabisere, Joseph Musaazi, Paolo Denti, Florence Aber, Mohammed Lamorde, Kelly E. Dooley, Rob Aarnoutse, Derek James Sloan, Christine Sekaggya-Wiltshire

School/Research organisations

Abstract

Background Tuberculosis (TB) is a significant public health problem that causes substantial morbidity and mortality. Current first-line anti-TB chemotherapy, although very effective, has limitations including long-treatment duration with a possibility of non-adherence, drug interactions, and toxicities. Dose escalation of rifampicin, an important drug within the regimen, has been proposed as a potential route to higher treatment efficacy with shorter duration and some studies have suggested that dose escalation is safe; however, these have almost entirely been conducted among human immunodeficiency (HIV)-negative TB patients. TB-HIV co-infected patients on antiretroviral therapy (ART) are at increased risk of drug-drug interactions and drug-related toxicities. This study aims to determine the safety of higher doses of rifampicin and its effect on the pharmacokinetics of efavirenz (EFV) and dolutegravir (DTG) in TB-HIV co-infected patients.

Methods This study is a randomized, open-label, phase IIb clinical trial among TB-HIV infected adult outpatients attending an HIV clinic in Kampala, Uganda. Patients newly diagnosed with TB will be randomized to either standard-dose or high-dose rifampicin (35 mg/kg) alongside standard TB treatment. ART-naïve patients will be randomly assigned to first-line ART regimens (DTG or EFV). Those who are already on ART (DTG or EFV) at enrollment will be continued on the same ART regimen but with dose adjustment of DTG to twice daily dosing. Participants will be followed every 2 weeks with assessment for toxicities at each visit and measurement of drug concentrations at week 6. At the end of intensive-phase therapy (8 weeks), all participants will be initiated on continuation-phase treatment using standard-dose rifampicin and isoniazid.

Discussion This study should avail us with evidence about the effect of higher doses of rifampicin on the pharmacokinetics of EFV and DTG among TB-HIV co-infected patients. The trial should also help us to understand safety concerns of high-dose rifampicin among this vulnerable cohort.

Trial registration ClinicalTrials.gov, ID: NCT03982277. Registered retrospectively on 11 June 2019.
Close

Details

Original languageEnglish
Article number181
Number of pages9
JournalTrials
Volume21
DOIs
Publication statusPublished - 13 Feb 2020

    Research areas

  • Rifamycins, Antiretrovirals, HIV, Pharmacokinetics, Tuberculosis

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. PrimeStore MTM and OMNIgene sputum for the preservation of sputum for Xpert MTB/RIF testing in Nigeria

    Bimba, J. S., Lawson, L., Kontogianni, K., Edwards, T., Ekpenyong, B. E., Dodd, J., Adams, E. R., Sloan, D. J., Cresswell, J., Dominguez, J. & Cuevas, L. E., 4 Dec 2019, In : Journal of Clinical Medicine. 8, 12, 9 p., 2146.

    Research output: Contribution to journalArticle

  2. Defining the roles of Data Manager and Epidemiologist in emergency medical teams

    Bartolucci, A., Jafar, A. JN., Sloan, D. J. & Whitworth, J., 16 Oct 2019, In : Prehospital and Disaster Medicine. First View, 7 p.

    Research output: Contribution to journalArticle

  3. Genetic diversity of Mycobacterium tuberculosis clinical isolates in Blantyre, Malawi

    Ndhlovu, V., Kiran, A., Sloan, D., Mandala, W., Kontogianni, K., Kamdolozi, M., Caws, M. & Davies, G., Oct 2019, In : Heliyon. 5, 10, 5 p., e02638.

    Research output: Contribution to journalArticle

  4. A tuberculosis molecular bacterial load assay (TB-MBLA)

    Sabiiti, W., Mtafya, B. A., Alferes De Lima, D., Dombay, E., Baron, V. O., Azam, K., Orascova, K., Sloan, D. J. & Gillespie, S. H., 6 Sep 2019, (Accepted/In press) In : Journal of Visualized Experiments.

    Research output: Contribution to journalArticle

  5. Protocol for the development of the STrengthening the Reporting of Pharmacogenetic Studies (STROPS) guideline: checklist of items for reporting pharmacogenetic studies

    Richardson, M., Kirkham, J. J., Dwan, K. M., Sloan, D. J., Davies, G. & Jorgensen, A., 11 Jul 2019, In : BMJ Open. 9, 7, 5 p., e030212.

    Research output: Contribution to journalArticle

Related by journal

  1. Trial Forge Guidance 2: how to decide if a further Study Within A Trial (SWAT) is needed

    Treweek, S., Bevan, S., Bower, P., Briel, M., Campbell, M., Christie, J., Collett, C., Cotton, S., Devane, D., El Feky, A., Galvin, S., Gardner, H., Gillies, K., Hood, K., Jansen, J., Littleford, R., Parker, A., Ramsay, C., Restrup, L., Sullivan, F. & 7 others, Torgerson, D., Tremain, L., von Elm, E., Westmore, M., Williams, H., Williamson, P. R. & Clarke, M., 7 Jan 2020, In : Trials. 21, 9 p., 33.

    Research output: Contribution to journalArticle

  2. Factors associated with recruitment to randomised controlled trials in general practice: protocol for a systematic review

    Moffat, K. R., Cannon, P., Shi, W. & Sullivan, F., 10 May 2019, In : Trials. 20, 4 p., 66.

    Research output: Contribution to journalArticle

  3. The effect of optimised patient information materials on recruitment in a lung cancer screening trial: an embedded randomised recruitment trial

    Parker, A., Knapp, P., Treweek, S., Madhurasinghe, V., Littleford, R., Gallant, S., Sullivan, F., Schembri, S., Rick, J., Graffy, J., Collier, D. J., Eldridge, S., Kennedy, A. & Bower, P., 18 Sep 2018, In : Trials. 19

    Research output: Contribution to journalArticle

  4. Trial Forge Guidance 1: what is a Study Within A Trial (SWAT)?

    Treweek, S., Bevan, S., Bower, P., Campbell, M., Christie, J., Clarke, M., Collett, C., Cotton, S., Devane, D., El Feky, A., Flemyng, E., Galvin, S., Gardner, H., Gillies, K., Jansen, J., Littleford, R., Parker, A., Ramsay, C., Restrup, L., Sullivan, F. & 4 others, Torgerson, D., Tremain, L., Westmore, M. & Williamson, P. R., 23 Feb 2018, In : Trials. 19, 5 p., 139.

    Research output: Contribution to journalArticle

ID: 266337553

Top